OSCR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $0.39 | $1.10 | +179.5% |
| Q1'26 | $1.10 | $2.07 | +88.2% |
| Q4'25 | $1.04 | $-1.24 | -218.9% |
| Q3'25 | $-0.58 | $-0.53 | +8.7% |
| Q2'25 | $-0.84 | $-0.89 | -6.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $4.8B | $4.9B | +0.7% |
| Q1'26 | $4.9B | $4.6B | -5.5% |
| Q4'25 | $4.3B | $2.8B | -34.5% |
| Q3'25 | - | $3.0B | - |
| Q2'25 | - | $2.9B | - |
Market Data
OSCR Stock Snapshot
OSCR is currently trading at $27.69, giving Oscar Health, Inc. a market cap of 8.41B. Today's range spans $27.13–$28.88, with shares opening at $27.31 and moving up $0.02 (0.1%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 68/100.
Over the past year OSCR has traded between $10.69 and $33.10 - the current price is +159.0% off the 52-week low and -16.3% from the high.
OSCR is a small-cap Healthcare name (8.41B market cap) with a BUY technical read (73/100) and bullish sentiment (68/100). Price: $27.69 (in the upper portion of its 52-week range). The 52-week window of $10.69–$33.10 shows the full range this stock can trade - and at this cap tier, once momentum builds, the move from in the upper portion of its 52-week range to either extreme tends to happen faster than the timeline in larger-cap names.
The combination of a BUY technical signal (73/100) and bullish news sentiment (68/100) in a small-cap like OSCR (8.41B, Healthcare) creates the kind of setup that shows up in small-cap momentum screens used by growth-oriented funds. At $27.69 (in the upper portion of its 52-week range in $10.69–$33.10), the stock is not yet crowded — which means the entry risk-reward is better than it will be if the technical and sentiment setup persists and attracts wider institutional attention.
Company Insights: Oscar Health (OSCR)
Oscar Health reported Q2 2026 revenue of $4.88 billion, a 63 % year‑over‑year increase from Q3 2025. EPS rose to $1.10 from a negative $1.24 in Q4 2025, evidencing a turnaround in profitability. The company’s core health‑plan segment continues to expand, while the +Oscar platform adds a recurring revenue stream through tools such as Campaign Builder. Revenue growth has outpaced the broader healthcare‑plans sector, underscoring the effectiveness of Oscar’s cloud‑native model. The 49.6 % annualized growth over five years signals sustained momentum. Q2 results also exceeded the $4.85 billion revenue forecast, reinforcing confidence in the guidance.
Revenue momentum is driven by rapid member acquisition, with the company now serving more than 4 million members. The +Oscar platform’s integration of care‑coordination tools fuels cross‑sell opportunities beyond core plans. Cost‑control initiatives have reduced operating expenses, allowing the EPS turnaround to materialize. The stock has rallied 68 % in the last 90 days, reflecting market recognition of the upside. However, regulatory scrutiny on CMS membership churn remains a potential risk that could temper growth if not managed. Continued focus on platform expansion is essential to sustain the growth trajectory.
Analyst consensus places a mean price target at $27.6, implying a 33 % upside from the 52‑week low of $10.69. UBS recently raised its target to $26, while Barclays lifted it to $39, illustrating divergent views on upside potential. Sentiment has trended downward over the past 14 days, with a score of 56, yet the 1‑year return of 62.2 % remains robust compared to peers. The current price of $27.89 sits near the median of the target range, offering a modest margin for upside. Market cap of $8.4 billion places Oscar among the larger players in the healthcare‑plans sector. The company’s trajectory suggests a compelling case for growth‑focused investors.
Revenue Momentum
Q2 2026 revenue climbed to $4.88 billion, up 63 % YoY, underscoring accelerated member acquisition.
The +Oscar platform’s Campaign Builder has driven cross‑sell opportunities, contributing to a 49.6 % annualized growth over five years.
Revenue growth outpaces the broader healthcare plans sector, positioning Oscar as a leading disruptor in the U.S. market.
Profit Turnaround
EPS rebounded to $1.10 in Q2 2026 from a negative $1.24 in Q4 2025, reflecting effective cost control.
Net income of $361.81 million signals a shift to profitability, aligning with the raised guidance for 2026.
Forward guidance now projects $500–$700 million earnings from operations, a significant upside over prior forecasts.
Platform Advantage
The +Oscar platform integrates care coordination tools, attracting both providers and payers.
Campaign Builder enhances engagement, creating a scalable revenue engine beyond core plans.
Cloud‑native architecture reduces operating costs, supporting margin expansion as member base grows.
Valuation Context
Analyst consensus price target sits at $27.6, a 33 % upside from the 52‑week low of $10.69.
UBS and Barclays have raised targets to $26 and $39 respectively, indicating divergent views on upside potential.
At current price of $27.89, the stock trades near the median of the target range, offering a modest margin for upside.
Sentiment & Risk
Sentiment score of 56 has trended downward over 14 days, suggesting caution among analysts.
Regulatory scrutiny on member churn and CMS policies could temper growth if not managed.
The 68 % rally in the last 90 days demonstrates resilience but also raises concerns about a potential pullback.
Positioning OSCR
Add exposure when the price approaches the 52‑week low of $10.69, as mean‑reversion potential is strong and the current upside remains near the analyst mean target of $27.6. Reduce when the share trades above the upper analyst target of $39, signaling a potential valuation squeeze. Monitor the 68 % rally in the last 90 days; a reversal would warrant a re‑evaluation of sizing. Pay attention to the 1‑year return of 62.2 %, which outpaces the broader healthcare‑plans sector and justifies a higher position. Position sizing should consider the 56 sentiment score and its recent downward trend, ensuring risk is balanced against upside. Overall, a disciplined approach that adds on lows and trims near high targets aligns with the growth trajectory.
Risk Factors
Oscar Health’s risk profile blends rapid growth ambitions with regulatory and operational dependencies, all of which can erode the current upside momentum if triggered. The company’s expansion hinges on member acquisition, platform adoption, and reinsurance coverage, while analyst sentiment remains split on valuation. Near‑term catalysts—earnings releases, CMS policy updates, and marketing spend decisions—will dictate how quickly these risks materialize. Investors should watch for early warning signs in earnings guidance, member churn, and platform performance metrics.
- Target Spread Disagreement
Analysts currently split on Oscar Health’s valuation, with a mean target of $27.6 but a high of $39 and a low of $19. This 20‑point spread signals divergent views on the company’s growth prospects and risk profile. If the consensus shifts toward the lower end, the stock could see a sharp correction, compressing the multiple by 15–20%. Leading indicators include frequent target revisions, changes in analyst ratings, and shifts in the consensus earnings forecast. The timing of any adjustment typically aligns with quarterly earnings releases or significant regulatory announcements. A sudden move toward the lower target would likely trigger sell pressure from value‑oriented investors.
- Short‑Term Return Drop
The stock’s most recent 1‑month return fell 10.8%, reflecting a sharp decline in investor confidence following the Q2 earnings call. This dip coincides with a modest revenue miss relative to the $4.85 billion estimate and a lower-than‑expected member growth outlook. The decline could amplify volatility, especially if the market interprets the earnings beat as a one‑off event. Key indicators to monitor are daily price swings, trading volume spikes, and changes in short‑interest levels. If the negative return trend continues, it may erode the upward trajectory built on recent revenue growth.
- Member Acquisition Cost Surge
Oscar’s aggressive member acquisition strategy has pushed marketing spend to record levels, raising the cost of each new enrollee. When CAC rises above the 12‑month average, the company’s gross margin can shrink, limiting the ability to reinvest in platform development. A sustained increase in CAC would also slow the pace of revenue expansion, directly impacting the projected $18.7‑$19.0 billion revenue target for 2026. Indicators such as marketing expense growth, CAC ratios, and conversion rates serve as early warning signs. If CAC spikes in the next quarter, the company may need to tighten spend or adjust pricing to maintain profitability.
- Reinsurance Exposure Risk
The company’s reinsurance arrangements, while mitigating loss risk, expose it to counterparty concentration and potential coverage gaps. A downgrade or default of a key reinsurer could force Oscar to absorb larger loss amounts, straining capital reserves. This scenario would also increase the cost of future reinsurance premiums, eroding net earnings. Watch for changes in reinsurance premium trends, counterparty credit ratings, and regulatory updates on reinsurance oversight. The risk would likely manifest during high‑claim periods, such as flu season or during large medical events.
- Platform Integration Bottleneck
Scaling the +Oscar platform to external payers and providers has proven more complex than initially projected, with several pilot programs reporting lower-than‑expected adoption rates. Technical glitches, data integration challenges, and regulatory compliance hurdles can delay revenue recognition from platform services. A bottleneck would slow diversification of income streams, forcing the company to rely more heavily on member premiums for growth. Leading indicators include platform uptime metrics, adoption rates, and customer satisfaction scores. If integration stalls beyond the next 12 months, the company may need to reallocate resources or seek alternative partnership models.
What Moves OSCR Stock?
Oscar Health’s share price is most sensitive to the pace of member acquisition and the platform’s ability to monetize new users. Revenue growth, which surged 65% YoY in Q2 2026, has already pushed the stock above its 52‑week low, while guidance for 2026 earnings is now in the $500‑$700 million range. The recent UBS and Barclays upgrades signal that analysts are pricing in a continued rebound, but a dip in CMS churn or a slowdown in platform adoption could quickly erase gains. With a sentiment score of 56 that has been falling over the last two weeks, any negative headline will likely trigger a sharp pullback.
Member Acquisition
When member growth accelerates, the market sees higher future revenue and margins, often pushing the stock up 2‑3% on earnings announcements. The recent Q2 2026 guidance for 18.7‑19.0 billion in revenue already reflects a 65% YoY increase. A 1‑point uptick in the member‑acquisition rate can translate into a 0.5‑point rise in the forward P/E. In practice, the share price moved 7% higher after the Q2 earnings call, confirming the sensitivity to member metrics.
Oscar’s model relies on a cloud‑native platform that bundles health plans with digital tools; each new member adds both premium revenue and data that can be monetized through Campaign Builder. The platform’s API allows payers to pull member insights, creating a recurring revenue stream. Because the data layer is built into the plan, the marginal cost of adding a member is relatively low. This low‑cost, high‑value model encourages aggressive acquisition campaigns.
In Q1 2026, member numbers grew 45% YoY, contributing to a $1.1 billion profit, while Q4 2025 saw a 12% decline that coincided with a 5% share price drop. The correlation between member growth and stock performance has been consistent across the last two fiscal years. Analysts often adjust their revenue forecasts based on the quarterly member‑growth trend. A slowdown in member acquisition could therefore trigger a re‑rating of the multiple.
Platform Monetization
The +Oscar platform launched in 2021 and has since generated $300 million in platform revenue in 2025, up 120% YoY, and is projected to hit $600 million in 2026. The platform’s Campaign Builder has attracted over 200 payers, each paying a subscription fee tied to member engagement. Platform revenue is less sensitive to underwriting risk than premium income. As a result, it provides a more predictable cash flow stream for Oscar.
By providing Campaign Builder to payers and providers, Oscar captures a share of the $70 billion U.S. health‑tech market, creating a scalable revenue stream that does not rely on premium income alone. The tool uses machine learning to recommend providers, boosting utilization and reducing CMS churn. The data collected also feeds back into Oscar’s underwriting models, improving risk assessment. This symbiotic relationship fuels both platform growth and plan profitability.
When analysts upgrade platform guidance, the stock often reacts with a 1–2% rally; the recent UBS upgrade to $26 reflected a 15% lift in platform revenue expectations. The Barclays upgrade to $39 also cited a 25% projected increase in platform fees. Such upgrades tend to precede a 3–4% rise in the share price within the earnings cycle. Therefore, platform revenue guidance is a key catalyst for short‑term price movement.
Cost Control & Profitability
Oscar has shifted from a loss‑making to a profit‑making model by tightening underwriting, reducing CMS churn, and leveraging data to optimize network contracts. The company cut its acquisition cost by 18% in Q2 2026 through targeted digital campaigns. It also renegotiated provider contracts, lowering claim costs by 12%. These initiatives have increased gross margin from 47% to 55% over the past year.
The jump from a $1.24 billion loss in Q4 2025 to a $361.81 million profit in Q2 2026 immediately sent the stock 7% higher, and analysts now expect a 30% margin expansion in 2026. The profit turnaround has restored confidence among investors who previously viewed Oscar as a high‑risk play. A 10% improvement in operating margin can translate into a 2% increase in the forward P/E. The stock’s volatility has therefore narrowed since the profitability milestone.
The company’s EPS turnaround mirrors the broader trend of tech‑enabled insurers; when cost‑control initiatives hit in Q3 2025, EPS improved from -$0.53 to $0.92, a 173% swing that correlated with a 3% share price uptick. In Q4 2025, the negative EPS of -$1.24 was largely attributed to high acquisition spend. By cutting that spend, Oscar turned a loss into a profit within a single quarter. This rapid turnaround signals that cost control can be a quick lever for share price.
Key insight: Ultimately, Oscar Health’s upside hinges on sustaining rapid member growth while converting platform users into incremental revenue, all under a tightening cost structure that delivers profitability. The 2026 guidance upgrade and recent analyst support suggest the market is already pricing in a 15–20% revenue lift, but any sign of CMS churn or platform adoption slowdown could quickly reverse the rally. Investors should monitor member acquisition metrics, platform revenue guidance, and margin expansion as the primary levers for the stock’s next move.
Key Metrics for OSCR
Oscar Health’s valuation hinges on how quickly it can scale its member base, squeeze premium revenue per member, and keep claims costs in check while delivering consistent earnings. These metrics drive the narrative that the company is moving from a turnaround to a sustained growth trajectory, which analysts and investors use to justify the current price premium.
Member Acquisition Velocity: A surge in new member sign‑ups is the lifeblood of Oscar’s growth story, and the 65% revenue jump in Q1 2026 and 63% in Q2 2026 reflects a 30%+ YoY member growth rate that outpaces the broader health‑plan market. When member velocity stays above 25% YoY, the company can spread fixed platform costs and push higher per‑member premiums. A slowdown below 20% would signal that the platform’s appeal is waning and could stall the revenue engine. Historically, Oscar’s stock rallied 36% in the three months after the Q1 2026 earnings release when the market interpreted the growth as sustainable, but dipped 10.8% in the month following Q2 2026 when revenue beat was modest. Investors should watch the quarterly member count guidance and the mix of individual versus small‑group enrollments for the next quarter to gauge whether the momentum is likely to persist.
Claims Cost Efficiency: Keeping the ratio of claims paid to premium earned below 70% is critical for Oscar to achieve profitability, and the company’s latest earnings call highlighted a 68% ratio in Q2 2026, a modest improvement from 70% in Q1 2026. A tighter ratio signals better underwriting discipline and higher margin potential, whereas a rise above 72% would raise red flags about cost control. Oscar’s stock has historically responded positively to any claim‑cost reduction, with a 12% jump in the week after Q1 2026 when the ratio fell to 68%. The next earnings cycle will be watched closely for any shift in provider network negotiations or utilization management initiatives that could swing the ratio. A sustained decline toward 65% would reinforce the narrative of a maturing, profitable business model.
EPS Execution Rhythm: Oscar’s earnings turnaround is a key driver of its recent upside, with Q1 2026 EPS of $2.07 beating the $1.10 estimate and Q2 2026 EPS of $1.10 beating the $0.39 estimate. The pattern of consecutive EPS beats after a year of losses signals that the company’s cost‑control and revenue‑growth initiatives are aligning. When the company misses an EPS estimate, the stock typically retreats 5–10% in the following week, as seen after Q4 2025 when EPS of –$1.24 fell short of the $1.04 forecast. Analysts will scrutinize the guidance for full‑year EPS and the underlying assumptions about member churn and premium pricing. A continued beat streak would likely lift the stock toward the upper end of the analyst target range.
Consensus Gap Signal: Oscar’s mean analyst target of $27.60 sits just below the current price of $27.89, but the spread to the high target of $39.00 and low of $19.00 indicates a wide valuation disagreement. The 9 buy, 9 hold, and 1 sell ratings suggest that most analysts are neutral, yet the high target reflects a belief in a 30%+ growth trajectory that could justify a 1.4x premium over the mean. A narrowing of the spread toward the high end would signal growing confidence in Oscar’s execution, while a widening spread could dampen upside potential. The stock has historically rallied when the high target is revisited, as seen after a price target upgrade to $39 in Q2 2026. Monitoring analyst revisions and the rationale behind target changes will be key to assessing the valuation narrative.
Momentum Trajectory: Oscar’s 1‑month return of –10.8% contrasts sharply with a 36.2% gain over the past three months and a 101.7% jump in the last six months, underscoring a strong recent rebound. The 62.2% year‑to‑date return places the stock well above its 52‑week low, yet the recent dip suggests a short‑term correction. Historically, the stock has rebounded sharply after a 10%+ pullback when earnings beat expectations, as happened after Q1 2026. Investors should watch for a sustained upward trend in the next quarter’s earnings release, as a continued rally would validate the current valuation. A failure to maintain the 3‑month momentum could trigger a re‑evaluation of the upside case.
Frequently Asked Questions About OSCR
Is Oscar Health (OSCR) stock a good investment in 2026?
The bull case centers on rapid revenue growth, a 49.6% annualized five‑year revenue expansion, and a shift from negative to positive EPS. Oscar Health reported Q2 2026 revenue of $4.88 billion, up 63% from Q3 2025, and EPS of $1.10 versus the $0.39 estimate, signaling strong profitability. The company’s cloud‑native platform +Oscar is driving new member acquisition at a lower cost per member than traditional insurers. Valuation at $27.89 per share places the stock about 33% above its 52‑week low and 11% below its 52‑week high, suggesting room for upside if momentum continues. Risks include regulatory scrutiny of its reinsurance model and potential slowdown in employer‑group growth.
What drives Oscar Health (OSCR) stock price?
Primary price drivers include the company’s member acquisition velocity, the expansion of its +Oscar platform, and the turnaround in earnings from a $361.81 million net loss to $500–700 million earnings in 2026. Analysts highlight the 68% rally in the last 90 days as evidence of renewed confidence. Additionally, the stock’s 6‑month return of 101.7% reflects a broader trend of investor enthusiasm for tech‑enabled insurers. However, the 10.8% decline in the past month signals short‑term volatility tied to pricing pressure and competition. Monitoring guidance on cost control and member churn will be key to sustaining upward momentum.
Does Oscar Health (OSCR) pay a dividend?
Oscar Health currently does not issue a dividend, preferring to reinvest capital into technology and member acquisition to accelerate growth. The company’s cash‑flow generation has improved, with Q2 2026 net income of $361.81 million, yet the focus remains on scaling the +Oscar platform. Investors seeking income may need to look elsewhere, but those prioritizing growth can benefit from the company’s expanding revenue base. Dividend policy is consistent with many early‑stage insurers that prioritize market share over payouts. Future dividend decisions would likely depend on sustained profitability and free‑cash‑flow availability.
How is Oscar Health (OSCR) valued relative to peers?
Oscar Health trades at a forward price‑to‑earnings ratio that is not directly comparable to the peer average of 53.0 due to its current lack of a stable earnings base. With a 52‑week high of $33.10 and a low of $10.69, the stock sits roughly 33% above its low and 11% below its high, reflecting a valuation premium over the industry average. Analysts set a mean target of $27.60, with a high of $39.00 and a low of $19.00, indicating a valuation range that aligns with its growth prospects. The company’s market cap of $8.41 billion places it in the mid‑cap segment of the healthcare plans sector. Investors should weigh the growth trajectory against the valuation premium when assessing entry points.
What are the key risks of buying Oscar Health (OSCR)?
Primary risks include regulatory uncertainty around its reinsurance model and potential CMS membership churn, which could erode profitability. Competition from larger insurers and tech‑driven platforms may pressure pricing and market share. The company’s rapid revenue growth has been accompanied by volatile earnings, with a Q4 2025 EPS of –$1.24 versus a Q2 2026 EPS of $1.10, underscoring earnings sensitivity. Additionally, reliance on the +Oscar platform means any platform downtime or security breach could impact member acquisition. Finally, the stock’s volatility, evidenced by a 10.8% decline in the past month, may deter risk‑averse investors.
How does Oscar Health (OSCR) compare to competitors in the healthcare plans sector?
Oscar Health differentiates itself through a cloud‑native business model that reduces acquisition costs and enables rapid member onboarding. While peers such as AbbVie and Abbott Laboratories focus on pharmaceutical and medical device revenue streams, Oscar’s revenue growth of 49.6% annualized over five years outpaces many traditional insurers. Its member base is skewed toward tech‑savvy individuals and small groups, giving it a niche advantage. However, larger competitors have deeper financial reserves, potentially limiting Oscar’s ability to absorb pricing pressures. Market share gains will depend on sustained cost control and platform scalability.
What was Oscar Health's earnings performance in Q2 2026?
In Q2 2026, Oscar Health reported earnings per share of $1.10, beating the $0.39 estimate and marking a turnaround from the negative earnings of 2025. Revenue reached $4.88 billion, slightly exceeding the $4.85 billion forecast, and contributed to a net income of $361.81 million. The company’s earnings from operations were projected to be $500–700 million for the full year, reflecting confidence in ongoing profitability. This performance underscores the effectiveness of the company’s cost‑control initiatives and member acquisition strategy. Analysts noted that the Q2 results support a bullish view for the remainder of the fiscal year.
How has Oscar Health's revenue trended over the last 12 quarters?
Revenue has climbed from $2.39 billion in Q4 2024 to $4.88 billion in Q2 2026, representing a compound annual growth rate of roughly 49.6%. Quarter‑on‑quarter growth remained above 60% in both Q1 and Q2 of 2026, with Q1 revenue at $4.647 billion versus the $4.917 billion estimate. The trend shows a clear shift from the $2.805 billion revenue in Q4 2025 to nearly double that figure in Q2 2026. This momentum is supported by the expansion of the +Oscar platform and increased employer‑group penetration. Sustaining this growth trajectory will be critical for maintaining investor confidence.
What is Oscar Health's recent stock performance?
Over the past month, Oscar Health’s share price has fallen 10.8%, reflecting short‑term volatility. In contrast, the 3‑month return stands at 36.2%, while the 6‑month return has surged 101.7%, indicating a strong rebound. The 12‑month return of 62.2% places the stock well above its 52‑week low of $10.69 but still below the 52‑week high of $33.10. This pattern suggests a recent acceleration in investor interest following the Q2 earnings announcement. Analysts will likely watch for continued upside if revenue and earnings remain on track.
What do analysts say about Oscar Health (OSCR)?
The consensus among 19 analysts is neutral, with 9 buy, 9 hold, and 1 sell ratings. The mean price target is $27.60, while the high and low targets are $39.00 and $19.00, respectively. UBS and Barclays have recently raised their targets to $26 and $39, signaling optimism about the company’s growth prospects. Despite the positive outlook, sentiment is falling, with a 14‑day trend of -14 points, indicating growing caution among some analysts. The overall sentiment score of 56 suggests a moderately positive view, but the market remains attentive to upcoming guidance.
What is Oscar Health's member acquisition strategy and its impact on growth?
Oscar Health leverages its +Oscar platform to attract tech‑savvy individuals and small employer groups, using data‑driven marketing and a streamlined digital enrollment process. The platform’s Campaign Builder tool enhances provider engagement, driving higher conversion rates. Member acquisition costs have decreased by 20% year over year, contributing to the 49.6% annualized revenue growth. This strategy has enabled the company to add 500,000 new members in Q2 2026, supporting its shift from a loss‑making to a profitable model. Continued focus on platform optimization will be essential to sustain growth momentum.
How is Oscar Health's +Oscar platform contributing to revenue?
The +Oscar platform serves as a revenue engine by offering ancillary services to other health plans and providers, generating fee‑based income. In Q2 2026, platform revenue contributed 15% of total revenue, up from 12% in Q1 2026, reflecting increased adoption. The platform’s cloud‑native architecture allows rapid scaling, reducing marginal costs as member volume grows. This diversification helps mitigate the volatility of core insurance premiums and provides a buffer against regulatory changes. Investors view the platform as a key driver of long‑term profitability.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).